Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at Los Angeles, California and other locations
- Dates
- study startedcompletion around
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Alexion Pharmaceuticals, Inc.
- Links
- Sign up for this study
- ID
- NCT05556096
- Phase
- Phase 3 Myasthenia Gravis Research Study
- Study Type
- Interventional
- Participants
- Expecting 254 study participants
- Last Updated